

Transcription of Brandes Paper Review

[Begin letterhead]

UNIVERSITY of LONDON

Royal Postgraduate Medical School

MRC Leukaemia Unit

[RPMS Logo] Hammersmith Hospital. London W12 OHS

Telephone: 01-743 2030 Ext:

Telegram: Postgradmed London W12 OHS

[End letterhead]

25th March, 1981

Dr. Lorne. J. Brandes,  
Assistant Professor,  
Department of Medicine,  
Manitoba Institute of  
Cell Biology,  
700 Bannatyne Avenue,  
Winnipeg,  
CANADA. R3E OV9

Dear Lorne,

Thank you for sending the manuscript which makes good sense to me and reads well. My only queries are first, p.2, bottom line, you do not say whether the cyclophosphamide was given weekly. On the next page you say 'weekly cyclophosphamide was continued' implying that it had been weekly from the start, but it would have been clearer to state the frequency at first mention, especially as this is of crucial importance to the whole argument. The second query concerns patient 2. Did she have courses of melphalan and prednisone throughout the period 1971 to January 1978?

I don't know what the Editor of the Lancet will think about the 'interest for the general reader'. As you know the Lancet's policy is fickle and unpredictable and, so far as I know, they hardly ever consult referees, aiming for a quick turnover. He might regard this as a minor subspecialty debate on the niceties of dosage scheduling which from the point of view of his 'general reader' he may regard as of trifling importance. I would be interested to know what happens. If he turns it down, wouldn't Cancer Chemotherapy Reports be [sp] the right place?

I have switched my first patient from oral to i.v. cyclophosphamide, but it is too early yet to know whether he will respond. Also, perhaps misunderstanding you on the telephone, I have been giving him prednisone only on the day of the injection and the following day. I shall switch him to alternate days from today. I have no other suitable patient at the moment.

With all good wishes.

Yours sincerely,

[Signature: David]

Professor D.A.G. Galton, MD, FRCP  
Hon. Director, MRC Leukaemia Unit